METHODS	A total of 1,314 patients with a primary tumor > 1.50 mm in thickness ( T3-4N0M0 ; American Joint Committee on Cancer stage II ) were randomly assigned to GM2-KLH/QS -21 vaccination ( n = 657 ) or observation ( n = 657 ) .\